Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

  1. Escudero-Vilaplana, V.
  2. Collado-Borrell, R.
  3. De Castro, J.
  4. Insa, A.
  5. Martínez, A.
  6. Fernández, E.
  7. Sullivan, I.
  8. Flores, A.
  9. Arrabal, N.
  10. Carcedo, D.
  11. Manzaneque, A.
Aldizkaria:
Journal of medical economics

ISSN: 1941-837X

Argitalpen urtea: 2023

Alea: 26

Zenbakia: 1

Orrialdeak: 445-453

Mota: Artikulua

DOI: 10.1080/13696998.2023.2188844 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus